Zurletrectinib, developed by InnoCare, is a pan-TRK inhibitor which markedly inhibits the activity of the wild type TRKA, TRKB and TRKC, as well as mutant ...
“The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipel...
Maureen Deehan, CEO of Vivtex, commented: “We are delighted to enter this new collaboration with Astellas Pharma. Over the past few years, Vivtex has...
Glass vials are regularly used for pharmaceutical packaging, though there is a growing market need for primary packaging that is suited to more sensitive, ...
BioPharma BoardRoom sat down with Simona Grandits, Senior Director, Head of Sales and Marketing EEMEA at QIAGEN, to delve into the company's recent strateg...
“We are very excited that our partner is moving forward with licensing the XeriJect technology to further the development of the XeriJect subcutaneou...
Underpinning this objective Rousseau outlines the investment achievements already notched up in 2023, to illustrate how SGD Pharma has paved the way for th...
Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer Potential benefit to 8 out of 10 plat...
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercial...
-- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 – -- Initial readout expected as ear...
Cell BioEngines, Inc., a clinical-stage biotechnology company focused on delivering novel, innovative stem cell and immune cell therapies to address blood ...
The new HPAPI GMP facility enables PharmaBlock to offer process R&D and kilo-scale production of HPAPIs and ADC toxins. It spans an area of 1000 m...
Approval Based on Phase 3 TAK-620-303 SOLSTICE Study Demonstrating Maribavir Was Superior to Conventional Therapies at Week 8, for Primary Endpoint1-...
Kite, a Gilead Company (Nasdaq: GILD), announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta® (axicabtage...
© 2025 Biopharma Boardroom. All Rights Reserved.
